Table 1.
Demographic characteristics of study patients, HIV testing rates and HIV seroprevalence, grouped by cancer diagnosis
| ICC |
NHL |
HL |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Tested | Not tested | Pa | Tested | Not tested | Pa | Tested | Not tested | Pa | |
| Number of patients [n (%)] | 6 (11) | 51 (89) | 392 (60) | 261 (40) | 79 (59) | 54 (41) | |||
| Number of men [n (%)] | NA | NA | – | 230 (59) | 161 (62) | > 0.5 | 44 (56) | 32 (59) | > 0.5 |
| Age (years) [median (IQR)] | 49 (36–58) | 54 (44–65) | > 0.5 | 57 (45–66) | 62 (52–74) | 0.01 | 32 (27–51) | 36 (27–59) | 0.6 |
| Married/widowed [n (%)] | 2 (33) | 26 (51) | > 0.5 | 276 (70) | 187 (72) | > 0.5 | 40 (51) | 29 (54) | > 0.5 |
| Origin [n (%)] | |||||||||
| Switzerland and North/West Europe | 4 (67) | 37 (73) | > 0.5 | 300 (77) | 219 (84) | 0.27 | 53 (67) | 38 (70) | > 0.5 |
| Other* | 2 (33) | 14 (27) | 92 (23) | 42 (16) | 26 (33) | 16 (30) | |||
| HIV-positive patients [total (n diagnosed at oncology work-up)] | 1 (0) | 23 (4) | 7 (0) | ||||||
| HIV seroprevalence, based on all patients as denominator [% (95% CI)]† | 1.7 (NA; < 5 HIV-positive patients†) | 3.4 (2.0–4.8) | 5 (1.4–8.6) | ||||||
| HIV seroprevalence, based on ‘tested’ patients only as denominator [% (95% CI)]† | 16 (NA; < 5 HIV-positive patients†) | 5.9 (3.6–8.2) | 8.9 (5.7–12.1) | ||||||
ICC, invasive cervical carcinoma; IQR, interquartile range; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; IQR, interquartile range; NA, not applicable.
P-values are specified where P < 0.5 (χ2 test); those for patient origin are calculated for patients from Switzerland and North/West Europe against those of all other origin.
Asia, Africa, South/East Europe, Middle East and America.
For cancer groups with testing rates < 100%, seroprevalence was calculated taking tested as well as all patients as the denominator, as assuming that all ‘not tested’ patients were HIV negative could underestimate true HIV seroprevalence. The 95% confidence interval (CI) is calculated for cancer groups with > 5 HIV-positive patients. The 10 Kaposi's sarcoma patients are not included in this table as HIV testing rate was 100%. Among these patients, nine (90%) were men, median age was 59 years (IQR 49–62 years), and seven (70%) were from Switzerland or North/West Europe; seroprevalence was six of 10 (60%), with four of the six patients being newly diagnosed at oncology work-up.